Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 July 2022 | Story Leonie Bolleurs | Photo Supplied
Riaz-Seedat
Prof Riaz Seedat, who enrolled for a PhD through the USDP, wishes to create ear, nose, and throat knowledge through his research that is more relevant to the South African setting.

Prof Riaz Seedat is Professor and Head of the Department of Otorhinolaryngology at the University of the Free State (UFS) and in the Free State Department of Health at the Universitas Academic Hospital. It is in this position where he has the opportunity to treat patients, teach students, and conduct research.

As one of the ten academics enrolled in the University Staff Development Programme (USDP), Prof Seedat forms part of the University Capacity Development Programme (UCDP), which seeks to transform academic expertise in the field of global health.

The UFS Office for International Affairs administers the programme, which offers an enriching journey for the group of academics from the University of the Free State (UFS) and the University of Venda (Univen).

In an interview, he revealed the importance of research focused on ENT cases in developing countries. 

How has your background shaped the life and academic path you have chosen? 

During my internship, I had the opportunity to work in ENT. The field sparked great interest in me, so I decided to specialise in it. 

During my training, it became apparent to me that much of the information in the literature was based on research and practices in developed countries and did not reflect the situation in developing countries, where there is a high burden of infectious diseases and presentation of patients with pathology at an advanced stage. My research has been focused on providing a developing country perspective of otorhinolaryngology, particularly with regard to infectious diseases and allergy in the field, creating ENT knowledge that is more relevant to the South African setting. 

What drew you to the USDP project’s call? 

The USDP provides me with the chance to complete my doctorate on recurrent respiratory papillomatosis, a disease that is characterised by recurrent wart-like growths on the surface of the vocal cords or tissue around the vocal cords.

In our context, this affects mostly children and there is a relatively high prevalence of this condition here in the Free State. Research through this PhD will expand knowledge on the diagnosis and management of the condition. 

Please tell us more about your research. 

I have identified that in South Africa, recurrent respiratory papillomatosis, which is caused by the human papillomavirus, occurs more commonly in children than in Europe, where mostly adults are affected. In future, I would like my research to find factors that can help to identify which patients with recurrent respiratory papillomatosis will develop more severe disease, in order to better treat them. 

I have also done work on infectious diseases such as HIV and ENT, describing the impact of HIV in the different ENT conditions we see. 

With regard to allergic rhinitis, we have studied the impact of the condition on patients’ quality of life and are identifying the most frequent allergens present in our setting here in the Free State.

Did the pandemic impact your research?

Yes, it did. Being a full-time clinician for the Free State Department of Health meant that we had to dedicate more time towards managing the pandemic. This has affected patient care and the research we do on the patients. Many patients could not access healthcare facilities because of the lockdown, impacting their treatment, as well as research being carried out. 

Global health is one of the critical issues for the future of the human species, especially in Africa, where both infectious and non-communicable diseases threaten development. What will your project contribute to the field? 

Many of the conditions I am researching are as a result of infectious diseases. Unfortunately, these are conditions that are often neglected as they occur mainly in developing countries. The research will positively impact society through the care and treatment of patients with the condition. 

What are your future career plans? How will a PhD qualification assist you in reaching these goals?

A PhD will help me obtain a better understanding of research content and methodologies. I believe that a PhD will also equip me with the knowledge to better supervise individuals who wish to further their academic careers and do their own PhDs. 

What is your advice for aspiring PhD candidates?

I would advise someone who wishes to complete a PhD to work on a topic that they have a great interest in, because it is a task that will take much of your time. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept